Consensus perspectives on prophylactic therapy for haemophilia: summary statement.

Erik Berntorp, Jan Astermark, S Björkman, V. S. Blanchette, K. Fischer, P. L. F. Giangrande, A. Gringeri, Rolf Ljung, M. J. Manco-Johnson, M. Morfini, R. F. Kilcoyne, P. Petrini, E. C. Rodriguez-Merchan, W. Schramm, A. Shapiro, H. M Van Den Berg, C. Hart

Research output: Contribution to journalLetterpeer-review

178 Citations (SciVal)
341 Downloads (Pure)


Participants in an international conference on prophylactic therapy for severe haemophilia developed a consensus summary of the findings and conclusions of the conference. In the consensus, participants agreed upon revised definitions for primary and secondary prophylaxis and also made recommendations concerning the need for an international system of pharmacovigilance. Considerations on starting prophylaxis, monitoring outcomes, and individualizing treatment regimens were discussed. Several research questions were identified as needing further investigation, including when to start and when to stop prophylaxis, optimal dosing and dose interval, and methods for assessment of long-term treatment effects. Such studies should include carefully defined cohorts, validated orthopaedic and quality-of-life assessment instruments, and cost-benefit analyses.
Original languageEnglish
Pages (from-to)41278
Issue numberSuppl 1
Publication statusPublished - 2003

Subject classification (UKÄ)

  • Hematology


Dive into the research topics of 'Consensus perspectives on prophylactic therapy for haemophilia: summary statement.'. Together they form a unique fingerprint.

Cite this